文献速递脑血管病

直接口服抗凝药与华法林在老年房颤合并缺血性卒中患者中的临床有效性:PROSPER研究

Clinical Effectiveness of Direct Oral Anticoagulants vs Warfarin in Older Patients With Atrial Fibrillation and Ischemic Stroke: Findings From the Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) Study.
PubMed 文献 · JAMA Neurol · 2019-01-01

DOACs组出院后第一年居家天数更多,主要不良心血管事件风险更低,死亡、再入院、出血性卒中及出血住院风险均较低,但胃肠道出血风险略高。

要点

  • 房颤合并缺血性卒中老年患者出院时使用DOACs较华法林有更多居家天数。
  • DOACs组主要不良心血管事件、死亡、再入院及出血性卒中风险更低。
  • DOACs组胃肠道出血风险略高于华法林。

核心结论

  • 在急性缺血性卒中合并房颤患者中,出院时使用DOACs与华法林相比与更好的长期结局相关。

主要发现

  • DOACs组出院后第一年平均居家天数为287.2天(SD 114.7),华法林组为263.0天(SD 127.3),调整后差异为15.6天(99% CI 9.0-22.1)。
  • DOACs组主要不良心血管事件的调整风险比为0.89(99% CI 0.83-0.96)。
  • DOACs组死亡风险比0.88(95% CI 0.82-0.95;P < .001),全因再入院风险比0.93(95% CI 0.88-0.97;P = .003),心血管再入院风险比0.92(95% CI 0.86-0.99;P = .02),出血性卒中风险比0.69(95% CI 0.50-0.95;P = .02),出血住院风险比0.89(95% CI 0.81-0.97;P = .009)。
  • DOACs组胃肠道出血风险比为1.14(95% CI 1.01-1.30;P = .03)。

临床怎么用

  • 对于65岁及以上房颤合并急性缺血性卒中的抗凝初治患者,出院时选择DOACs可能优于华法林以改善长期结局。
  • 临床决策时应权衡DOACs降低缺血事件和出血性卒中风险与轻度增加胃肠道出血风险之间的平衡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Current guidelines recommend direct oral anticoagulants (DOACs) over warfarin for stroke prevention in patients with atrial fibrillation (AF) who are at high risk. Despite demonstrated efficacy in clinical trials, real-world data of DOACs vs warfarin for secondary prevention in patients with ischemic stroke are largely based on administrative claims or have not focused on patient-centered outcomes. OBJECTIVE: To examine the clinical effectiveness of DOACs (dabigatran, rivaroxaban, or apixaban) vs warfarin after ischemic stroke in patients with AF. DESIGN, SETTING, AND PARTICIPANTS: This cohort study included patients who were 65 years or older, had AF, were anticoagulation naive, and were discharged from 1041 Get With The Guidelines-Stroke-associated hospitals for acute ischemic stroke between October 2011 and December 2014. Data were linked to Medicare claims for long-term outcomes (up to December 2015). Analyses were completed in July 2018. EXPOSURES: DOACs vs warfarin prescription at discharge. MAIN OUTCOMES AND MEASURES: The primary outcomes were home time, a patient-centered measure defined as the total number of days free from death and institutional care after discharge, and major adverse cardiovascular events. A propensity score-overlap weighting method was used to account for differences in observed characteristics between groups. RESULTS: Of 11 662 survivors of acute ischemic stroke (median [interquartile range] age, 80 [74-86] years), 4041 (34.7%) were discharged with DOACs and 7621 with warfarin. Except for National Institutes of Health Stroke Scale scores (median [interquartile range], 4 [1-9] vs 5 [2-11]), baseline characteristics were similar between groups. Patients discharged with DOACs (vs warfarin) had more days at home (mean [SD], 287.2 [114.7] vs 263.0 [127.3] days; adjusted difference, 15.6 [99% CI, 9.0-22.1] days) during the first year postdischarge and were less likely to experience major adverse cardiovascular events (adjusted hazard ratio [aHR], 0.89 [99% CI, 0.83-0.96]). Also, in patients receiving DOACs, there were fewer deaths (aHR, 0.88 [95% CI, 0.82-0.95]; P < .001), all-cause readmissions (aHR, 0.93 [95% CI, 0.88-0.97]; P = .003), cardiovascular readmissions (aHR, 0.92 [95% CI, 0.86-0.99]; P = .02), hemorrhagic strokes (aHR, 0.69 [95% CI, 0.50-0.95]; P = .02), and hospitalizations with bleeding (aHR, 0.89 [95% CI, 0.81-0.97]; P = .009) but a higher risk of gastrointestinal bleeding (aHR, 1.14 [95% CI, 1.01-1.30]; P = .03). CONCLUSIONS AND RELEVANCE: In patients with acute ischemic stroke and AF, DOAC use at discharge was associated with better long-term outcomes relative to warfarin.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Xian Y, Xu H, O'Brien EC, et al. Clinical Effectiveness of Direct Oral Anticoagulants vs Warfarin in Older Patients With Atrial Fibrillation and Ischemic Stroke: Findings From the Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) Study. JAMA Neurol. 2019. PMID: 31329212. doi:10.1001/jamaneurol.2019.2099

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。